Goldman Sachs Starts TherapeuticsMD (TXMD) at Buy
- S&P 500, Dow set to rise as economic growth heats up
- Didi (DIDI) Gains on WSJ Report It Considers Going Private, Company Denies
- Facebook (FB) Tops Profit and Revenue Estimates, But Shares Lower on Warning of Significant Growth Slowdown, Analyst Still Raises PT to a New 'Street High'
- Robinhood (HOOD) Priced IPO at Lower End of Range as Some Investors Stayed on Sidelines Over Frothy Valuation
- Hang Seng Index Rebounds as China Moves to Reassure Investors It Will Allow US IPOs
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Goldman Sachs initiated coverage on TherapeuticsMD (NYSE: TXMD) with a Buy rating and a price target of $10.00.
Shares of TherapeuticsMD closed at $6.62 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Atlantic Equities Starts Robinhood Markets (HOOD) at Overweight
- TherapeuticsMD to Report Second Quarter 2021 Results on August 4, 2021
- William O'Neil Starts Repligen (RGEN) at Buy
Create E-mail Alert Related CategoriesHot New Coverage, New Coverage
Related EntitiesGoldman Sachs
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!